Hydrazide CRM1 Modulators With Lower Toxicity and Brain Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small-molecule CRM1 inhibitors are toxic and poorly tolerated, limiting their therapeutic potential in treating disorders associated with abnormal cellular responses due to improper nuclear transport.
Innovation Solution
Development of novel hydrazide-containing nuclear transport modulators that exhibit selective CRM1 inhibition, providing therapeutic benefits while minimizing brain penetration and maintaining high systemic exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current small-molecule CRM1 inhibitors are used, then CRM1 inhibition is achieved, but toxicity increases and tolerability decreases
Solution Approach 1:
The patent modifies the chemical parameters of CRM1 inhibitors by incorporating specific hydrazide-containing moieties and controlling substitution patterns to reduce toxicity while preserving CRM1 inhibition efficacy. The compounds are designed with specific molecular weight ranges and functional group configurations that improve pharmacokinetic properties and reduce harmful effects.
Solution Approach 2:
The invention creates composite molecular structures combining hydrazide groups with various aromatic and heterocyclic systems. These composite structures integrate multiple functional elements that work synergistically to achieve selective CRM1 inhibition with improved safety profiles compared to simpler inhibitor molecules.
2Reliability
If current small-molecule CRM1 inhibitors are used, then CRM1 inhibition is achieved, but tolerability decreases
Solution Approach 1:
The patent optimizes pharmacokinetic parameters including oral bioavailability, half-life, and tissue distribution to improve therapeutic tolerability. The hydrazide-containing compounds are designed with molecular properties that enhance selective uptake in target tissues while minimizing exposure of healthy tissues, thereby improving tolerability.
Solution Approach 2:
The invention introduces metabolically stable intermediaries in the form of specific hydrazide linkages that protect the active CRM1-inhibiting moiety from premature degradation. These intermediary structures serve as protective groups that are cleaved only at the target site, reducing systemic toxicity and improving tolerability.
3Object-affected harmful factors
If brain penetration is reduced, then side effects are minimized, but therapeutic efficacy in CNS disorders may be limited
Solution Approach 1:
The patent designs compounds with local quality characteristics that enable selective tissue distribution. The hydrazide-containing molecules are engineered to preferentially accumulate in peripheral tissues and organs where CRM1 inhibition is most beneficial, while their reduced brain penetration spares the CNS from unwanted effects. This localized action enhances the therapeutic index.
Solution Approach 2:
The invention segments the therapeutic effect by creating compounds that selectively target peripheral CRM1-expressing tissues. The molecular structure is designed to interact with specific transport mechanisms in peripheral tissues while avoiding the blood-brain barrier, effectively segmenting the therapeutic action to where it is most needed and least likely to cause harm.
Data Source
AI summary
The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I:or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.